natgillin/translations-raw huggingface dataset:
• Do not repeat the activation process or you will not obtain 14 doses from your Lyxumia pen. 
• Ne ponavljajte postopka aktivacije, ker sicer iz peresnika Lyxumia ne boste dobili 14 odmerkov.
- you have a severe stomach or gut problem such as a disease of the muscles of the stomach called “gastroparesis” which results in delayed stomach emptying 
- če imate hude težave z želodcem ali črevesjem, npr. bolezen mišic želodca, imenovano gastroparezo, ki upočasni praznenje želodca.
Turn over 
Obrnite
Paracetamol was used as a model medicinal product to evaluate the effect of lixisenatide on gastric emptying. 
Paracetamol so uporabili kot modelno zdravilo za oceno vpliva liksisenatida na praznjenje želodca.
• Only use needles that are approved for use with Lyxumia. 
• Uporabljajte le igle, odobrene za uporabo s peresnikom Lyxumia.
The change in HbA1c from baseline was similar regardless of the antibody status (positive or negative). 
Sprememba HbA1c od izhodišča je bila podobna, ne glede na izvid protiteles (pozitiven ali negativen).
Do not activate this pen again. 
Tega peresnika ne aktivirajte več.
What if I forget to activate the Lyxumia pen or inject myself before activation? 
Kaj, če pozabim aktivirati peresnik Lyxumia, ali če si zdravilo injiciram pred aktivacijo?
The most frequently reported adverse reactions during clinical studies were nausea, vomiting and diarrhoea. 
Najpogosteje zabeleženi neželeni učinki v kliničnih študijah so bili navzea, bruhanje in driska.
During the 12-week run-in period, addition and titration of insulin glargine resulted approximately in an HbA1c decrease of 1%. 
Med 12-tedenskim obdobjem uvajanja sta dodatek in titriranje insulina glargina povzročila znižanje HbA1c za približno 1 %.
• Periodic safety update reports 
• Redna posodobljena poročila o varnosti zdravila (PSURs)
If a patient wishes to become pregnant, or pregnancy occurs, treatment with Lyxumia should be discontinued. 
Če bolnica želi zanositi ali če zanosi, je treba zdravljenje z zdravilom Lyxumia prekiniti.
Learning how to use the pre-filled pens Before you use the pen for the first time, your doctor or nurse will show how to inject Lyxumia. 
Naučite se uporabljati napolnjene injekcijske peresnike Preden boste prvič uporabili injekcijski peresnik, vam bosta zdravnik ali medicinska sestra pokazala, kako injicirati zdravilo Lyxumia.
• Once your Lyxumia pen is activated it can be used for up to 14 days. 
• Ko je peresnik Lyxumia aktiviran, ga lahko uporabljate do 14 dni.
This helps prevent contamination and potential needle blockage. 
To pomaga preprečiti kontaminacijo in morebitno zamašitev igle.
Table of activation and disposal In the table, write the date when you activated your pen and the date to throw it away 14 days later. 
Preglednica datumov aktivacije in datumov, ko je peresnik treba zavreči Sem vpišite datum, ko ste peresnik aktivirali, in datum, ko ga morate 14 dni pozneje zavreči.
• Allow your pen to warm at room temperature before using. 
• Pred uporabo pustite, da se peresnik ogreje na sobno temperaturo.
What Lyxumia is and what it is used for 2. 
Kaj je zdravilo Lyxumia in za kaj ga uporabljamo 2.
• Do not activate the purple 20 microgram Lyxumia pen until you have finished the green pen. 
• Ne aktivirajte škrlatnega peresnika Lyxumia 20 mikrogramov, dokler ne dokončate zelenega peresnika.
- you have or have had inflammation of the pancreas (pancreatitis) 
- če imate ali ste imeli vnetje trebušne slinavke (pankreatitis).
This is to make sure that it is working correctly and that the dose for your first injection is correct. 
Tako boste preverili njegovo pravilno delovanje in boste zagotovili, da je odmerek za vaše prvo injiciranje pravilen.
• Do not use Lyxumia after the expiry date which is stated on the label and on the carton. 
• Zdravila Lyxumia ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli.
Pen ready for injections (white window) 
Peresnik, pripravljen za injiciranje (belo okence)
• Throw away your Lyxumia pen, ask your pharmacist how to throw away medicines you no longer use. 
• Peresnik Lyxumia zavrzite, s farmacevtom se posvetujte o načinu odstranjevanja zdravil, ki jih ne potrebujete več.
Pharmacotherapeutic group: Drugs used in Diabetes, Glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ03 
Farmakoterapevtska skupina: Zdravila za zdravljenje diabetesa, analogi glukagonu podobnega peptida-1 (GLP-1), oznaka ATC: A10BJ03
The tmax of ramipril and ramiprilat were delayed by approximately 2.5 hours. 
tmax ramiprila in ramiprilata sta se podaljšala za približno 2,5 ure.
• The starting dose is 10 micrograms once a day for the first 14 days - injected using the green pen. 
• Začetni odmerek je 10 mikrogramov enkrat na dan prvih 14 dni - injiciran z zelenim peresnikom).
- you are taking other medicines, as there are other medicines such as antibiotics or stomach resistant tablets or capsules that should not stay too long in your stomach (see section Other medicines and Lyxumia) 
- če jemljete druga zdravila, npr. antibiotike ali gastrorezistentne tablete ali kapsule, ki v želodcu ne smejo ostati predolgo (glejte poglavje Druga zdravila in zdravilo Lyxumia).
• Drowsiness (somnolence) 
• zaspanost (somnolenca)
• Always use the pen as described in the “Instructions for Use”. 
• Peresnik vedno uporabljajte tako, kot je opisano v Navodilih za uporabo.
• Viral infection 
• virusne okužbe
Other medicines and Lyxumia 
Druga zdravila in zdravilo Lyxumia
• Activation is done to make sure that the pen is working correctly and that the dose for your first injection is correct. 
• Aktivacija je potrebna, da preverite pravilno delovanje peresnika in zagotovite, da je odmerek za vaše prvo injiciranje pravilen.
In a study in healthy volunteers, a transient rise in heart rate has been observed after administration of lixisenatide 20 mcg. 
V študiji pri zdravih prostovoljcih je bilo opaziti prehodno povečanje srčnega utripa po uporabi liksisenatida 20 mcg.
Each pen contains a different strength of Lyxumia. 
Vsak peresnik vsebuje drugačno jakost zdravila Lyxumia.
Uncommon side effect: may affect up to 1 in 100 people • Hives (urticaria) 
Občasni neželeni učinki: pojavijo se lahko pri največ 1 od 100 oseb • koprivnica (urtikarija)
If you have injected yourself before activating the pen, do not correct this by giving yourself a second injection. 
Če ste si zdravilo injicirali, ne da bi peresnik pred tem aktivirali, tega ne popravljajte s še enim injiciranjem.
Ninety-six percent of the patients in both treatment groups completed the study in accordance with the protocol and the vital status was known at the end of the study for 99.0% and 98.6% of the patients in the lixisenatide and placebo group, respectively. 
Šestindevetdeset odstotkov (96 %) bolnikov v obeh terapevtskih skupinah je študijo dokončalo v skladu s protokolom, vitalno stanje pa je bilo ob koncu študije znano za 99,0 % bolnikov v skupini z liksisenatidom in za 98,6 % bolnikov v skupini s placebom.
Type I glass cartridge with a (bromobutyl) rubber plunger, flanged caps (aluminium) with inserted laminated sealing disks (bromobutyl rubber on the inside and polyisoprene on the outside). 
Vložek iz stekla tipa I z (brombutilnim) gumijastim batom, obrobljenimi zaporkami (aluminij) z vstavljenimi laminiranimi zapornimi diski (brombutilna guma na notranji strani in poliizopren na zunanji strani).
When Lyxumia is added to existing metformin therapy, the current metformin dose can be continued unchanged. 
Če je zdravilo Lyxumia dodano obstoječemu zdravljenju z metforminom, se lahko metformin še naprej uporablja v nespremenjenem odmerku.
Always use a new needle for activation. 
Za aktivacijo vedno uporabite novo iglo.
The apparent volume of distribution after subcutaneous administration of lixisenatide (Vz/F) is approximately 100 L. 
Navidezni volumen porazdelitve po subkutani uporabi liksisenatida (Vz/F) je približno 100 L.
What you need to know before you use Lyxumia 3. 
Kaj morate vedeti, preden boste uporabili zdravilo Lyxumia 3.
Lixisenatide should be used with caution in patients receiving oral medicinal products that require rapid gastrointestinal absorption, require careful clinical monitoring or have a narrow therapeutic ratio. 
Liksisenatid je treba previdno uporabljati pri bolnikih, ki peroralno prejemajo zdravila, ki zahtevajo hitro gastrointestinalno absorpcijo, potrebujejo skrbno klinično spremljanje ali imajo ozko terapevtsko razmerje.
Do not share it with anyone else. 
Ne delite ga z nikomer drugim.
Use of glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with a risk of developing acute pancreatitis. 
Uporaba agonistov receptorjev glukagonu podobnega peptida 1 (GLP-1) je povezana s tveganjem za pojav akutnega pankreatitisa.
Tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other medicines. 
Obvestite svojega zdravnika ali farrmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero drugo zdravilo.
Lixisenatide is a peptide and is not metabolised by cytochrome P450. 
Liksisenatid je peptid in se ne presnavlja s citokromom P450.
Activation window 
Aktivacijsko okence
The safety and efficacy of lixisenatide in children and adolescents less than 18 years of age have not yet been established. 
Pri otrocih in mladostnikih, mlajših od 18 let, varnost in učinkovitost liksisenatida še nista ugotovljeni.
Follow all steps in Section 
Sledite vsem korakom, opisanim v 2. poglavju.
Allergic reactions have been reported in 0.4% of Lyxumia patients. 
Alergijske reakcije so bile zabeležene pri 0,4 % bolnikov, ki so prejemali zdravilo Lyxumia.
Hypoglycaemia (in combination with metformin alone) 
hipoglikemija (v kombinaciji z metforminom samim)
The AUC and Cmax of the active metabolite (ramiprilat) were not affected. 
AUC in Cmax aktivnega presnovka (ramiprilata) se nista spremenili.
• Injection site reactions (such as itching). 
• reakcije na mestu injiciranja (kot je srbenje)
The most frequent side effects reported with Lyxumia that may affect more than 1 in 10 users (frequency very common) were nausea (feeling sick) and vomiting. 
Najbolj pogosti neželeni učinki, opisani z zdravilom Lyxumia, ki se pojavijo pri več kot 1 od 10 uporabnikov (zelo pogosti) so slabost v želodcu (siljenje na bruhanje) in bruhanje.
How to activate your new Lyxumia pen Step 1 Pull off the pen cap and check the pen 
Kako aktivirate nov peresnik Lyxumia 1. korak Snemite pokrovček peresnika in peresnik preverite
The HbA1c reduction was significant with once daily administration, whether administered morning or evening. 
Znižanje HbA1c je bilo značilno pri uporabi enkrat na dan, zjutraj ali zvečer.
Section 4 - MOVING TO THE PURPLE PEN Completed use of the green 10 microgram pen 
4. poglavje - PREHOD NA ŠKRLATNI PERESNIK Dokončajte uporabo zelenega peresnika 10 mikrogramov
In 2-year subcutaneous carcinogenicity study in mice, 3 cases of adenocarcinoma in the endometrium were seen in the mid dose group with a statistically significant increase, corresponding to an exposure ratio of 97-fold. 
V 2-letni študiji kancerogenosti pri subkutani uporabi pri miših so v skupini s srednjo ravnjo odmerka ugotovili 3 primere adenokarcinoma v endometriju s statistično značilnim povečanjem ob 97-kratnem razmerju izpostavljenosti.
Pen needles are not included. 
Igle za peresnik niso priložene.
As opposed to both insulin glulisine treatment regimens, lixisenatide reduced body weight (table 5). 
V nasprotju z obema shemama zdravljenja, ki sta vključevali insulin glulizin, je liksisenatid zmanjšal telesno maso (preglednica 5).
In embryo-foetal development studies, malformations, growth retardation, ossification retardation and skeletal effects were observed in rats at all doses (5-fold exposure ratio compared to human exposure) and in rabbits at high doses (32-fold exposure ratio compared to human exposure) of lixisenatide. 
V študijah embrio fetalnega razvoja so malformacije, upočasnitev rasti, zapoznelo osifikacijo in skeletne učinke so opažali pri podganah pri vseh odmerkih (5-kratno razmerje izpostavljenosti v primerjavi z izpostavljenostjo pri človeku) ter pri kuncih pri velikih odmerkih (32-kratno razmerje izpostavljenosti v primerjavi z izpostavljenostjo pri človeku) liksenatida.
If not, do not use this Treatment Initiation pack. 
Če ni takšna, ne uporabite tega pakiranja za uvedbo zdravljenja.
- you have severe kidney disease or you are on dialysis as the use of this medicine will not be recommended 
- če imate hudo bolezen ledvic ali ste na dializi, ker uporaba tega zdravila v tem primeru ni priporočljiva.
Also check it has not passed the expiry date. 
Preverite tudi, da ni že pretekel rok uporabnosti.
In case of air bubbles see the “Questions and answers” section. 
Če opazite mehurčke, glejte poglavje "Vprašanja in odgovori".
In patients newly started on insulin, body weight remained almost unchanged in the lixisenatide group while an increase was shown in the placebo group. 
Bolnikom, ki so jim na novo uvedli insulin, se telesna masa v skupini z liksenatidom skoraj ni spremenila, v skupini s placebom pa se je povečala.
Lyxumia should not be used if it has been frozen. 
Zdravila Lyxumia se ne sme uporabiti, če je bilo zmrznjeno.
• Low blood sugar (when Lyxumia is taken with metformin) 
• nizek krvni sladkor (ce jemljete zdravilo Lyxumia z metforminom)
The pen is to be used for one patient only. 
Peresnik je namenjen za uporabo pri enem samem bolniku.
The Lyxumia Treatment Initiation pack includes two different coloured pens. 
Pakiranje za uvedbo zdravljenja z zdravilom Lyxumia vsebuje dva peresnika različnih barv.
What Lyxumia looks like and contents of the pack Lyxumia is a clear and colourless solution for injection (injection) filled in a glass cartridge inserted in a pre-filled pen. 
Izgled zdravila Lyxumia in vsebina pakiranja Zdravilo Lyxumia je bistra in brezbarvna raztopina za injiciranje (injekcija) v steklenem vložku, vstavljenem v napolnjen injekcijski peresnik.
As lixisenatide is cleared primarily by the kidney, no pharmacokinetic study has been performed in patients with acute or chronic hepatic impairment. 
Liksisenatid se izloča predvsem preko ledvic, zato farmakokinetičnih študij pri bolnikih z akutno ali kronično okvaro jeter niso izvedli.
The tmax of digoxin was delayed by 1.5 hour and the Cmax was reduced by 
tmax digoksina se je podaljšal za 1,5 ure in njegova Cmax se je znižala za
CV: cardiovascular, MI: myocardial infarction, HF: hospitalization for heart failure, Revasc: coronary revascularization procedure, HR: hazard ratio, CI: confidence interval. 
MI: miokardni infarkt, SP: sprejem v bolnišnico zaradi srčnega popuščanja, revask: koronarni revaskularizacijski postopek, ROg: razmerje ogroženosti, IZ: interval zaupanja.
Lixisenatide action is mediated via a specific interaction with GLP-1 receptors, leading to an increase in intracellular cyclic adenosine monophosphate (cAMP). 
Liksisenatid deluje preko specifične interakcije z receptorji GLP-1 in tako poveča znotrajcelično koncentracijo cikličnega adenozinmonofosfata (cAMP).
Women of childbearing potential Lyxumia is not recommended in women of childbearing potential not using contraception. 
Ženske v rodni dobi Zdravilo Lyxumia ni priporočljivo za ženske v rodni dobi, ki ne uporabljajo kontracepcije.
The incidence of hypoglycaemia was mainly increased in the lixisenatide group during the first 6 weeks of treatment and thereafter, was similar to the placebo group. 
Incidenca hipoglikemij se je med prejemniki liksisenatida povečala predvsem v prvih 6 tednih zdravljenja, pozneje pa je bila podobna kot med prejemniki placeba.
If such medicinal products are to be administered with food, patients should be advised to, if possible, take them with a meal when lixisenatide is not administered. 
Če mora bolnik takšna zdravila jemati s hrano, mu je treba svetovati, naj jih po možnosti vzame ob tistih obrokih, pri katerih ne vzame liksisenatida.
Pack sizes of 1, 2 or 6 pre-filled pens. 
Velikost pakiranj z 1, 2 ali 6 napolnjenimi peresniki.
Efficacy and safety of Lyxumia in patients older than 70 years was addressed in a specifically dedicated placebo-controlled study (176 patients randomised to lixisenatide, including 62 patients ≥75 years of age). 
Učinkovitost in varnost zdravila Lyxumia pri bolnikih, starejših od 70 let, je obravnavala posebna namenska, s placebom kontrolirana študija (176 bolnikov randomiziranih na liksisenatid, vključno z 62 bolniki, starimi ≥ 75 let).
The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. 
Receptor GLP-1 je ciljno mesto delovanja naravnega GLP-1; to je endogeni inkretinski hormon, ki poveča od glukoze odvisno izločanje insulina iz pankreatičnih celic beta.
A clinical study was conducted in insulin-naive patients insufficiently controlled on oral antidiabetic agents. 
Klinično študijo so izvedli pri bolnikih, ki še niso bili zdravljeni z insulinom in so bili nezadostno urejeni s peroralnimi antidiabetiki.
Secondary composite endpoints primary + HF primary + HF + Revasc 661 (21.8%) 659 (21.7%) Individual components of composites CV death 
Primarni + SP + revask 661 (21,8 %) 659 (21,7 %) Posamezni elementi sestavljenih opazovanih dogodkov Srčno-žilna smrt
This was also confirmed in an 8-week study versus liraglutide, administered before breakfast, in combination with insulin glargine with or without metformin. 
To je bilo potrjeno tudi v 8-tedenski študiji z liraglutidom zaužitim pred zajtrkom, v kombinaciji z insulinom glarginom z ali brez metformina.
No related effect on spermatogenesis was seen in healthy men. 
Pri zdravih moških niso ugotovili podobnega vpliva na spermatogenezo.
Step F. Repeat all steps in Section 3 for each injection. 
Korak F. Za vsako injiciranje ponovite vse korake, opisane v 3. poglavju.
Sulfonylureas or glinides were not used with basal insulin as background therapy. 
Sulfonilsečnine ali glinidi niso bili uporabljeni z bazalnim insulinom kot osnovno zdravljenje.
The ELIXA study was a randomized, double-blind, placebo-controlled, multinational study that evaluated cardiovascular (CV) outcomes during treatment with lixisenatide in patients with type 2 diabetes mellitus after a recent Acute Coronary Syndrome. 
Študija ELIXA je bila randomizirana, dvojno slepa, s placebom kontrolirana mednarodna študija, ki je ocenjevala srčno-žilne izide med zdravljenjem z liksisenatidom pri bolnikih s sladkorno boleznijo tipa 2 po nedavnem akutnem koronarnem sindromu.
Your doctor may want to control your blood sugar level and then, decide to reduce your dose of basal insulin or sulphonylurea. 
Zdravnik vam bo morda želel uravnati koncentracijo krvnega sladkorja in se bo potem odločil za zmanjšanje vašega odmerka bazalnega insulina ali sulfonilsečnine.
Following administration of a single dose of an oral contraceptive medicinal product (ethinylestradiol 0.03 mg/levonorgestrel 0.15 mg) 1 hour before or 11 hours after 10 mcg lixisenatide, the Cmax, AUC, t1/2 and tmax of ethinylestradiol and levonorgestrel were unchanged. 
Po uporabi enega samega odmerka peroralnega kontraceptiva (0,03 mg etinilestradiol/0,15 mg levonorgestrela) 1 uro pred ali 11 ur po uporabi 10 mcg liksisenatida se Cmax, AUC, t1/2 in tmax etinilestradiola in levonorgestrela niso spremenili.
Pen Date of activation 
Peresnik Datum aktivacije
This medicine contains metacresol which may cause allergic reactions. 
To zdravilo vsebuje metakrezol, ki lahko povzroči alergijske reakcije.
The most common adverse reactions which led to treatment discontinuation in the lixisenatide group were nausea (3.1%) and vomiting (1.2%). 
Najpogostejša neželena učinka, zaradi katerih so zdravljenje prekinili med prejemniki liksisenatida, sta bila navzea (3,1 %) in bruhanje (1,2 %).
As a peptide, lixisenatide is eliminated through glomerular filtration, followed by tubular reabsorption and subsequent metabolic degradation, resulting in smaller peptides and amino acids, which are reintroduced in the protein metabolism. 
Liksisenatid je peptid in se tako izloča z glomerularno filtracijo, ki ji sledi tubularna reabsorpcija in nadaljnja presnovna razgradnja; nastanejo manjši peptidi in aminokisline, ki se vrnejo v presnovo beljakovin.
• Post-prandial glucose 
• Postprandialna glukoza
Inject Lyxumia into the skin (subcutaneously) of your stomach area (abdomen), upper leg (thigh) or upper arm. 
Zdravilo Lyxumia injicirajte v kožo (podkožno) na trebuhu, zgornjem delu noge (stegnu) ali zgornjem delu roke.
Grasp a fold of skin and insert the needle (see the “Injection sites” section about where to inject). 
Primite kožno gubo in zabodite iglo (glejte poglavje "Mesta injiciranja" za informacije o tem, kam injicirati zdravilo).
Very common side effects: may affect more than 1 in 10 people 
Zelo pogosti neželeni učinki: pojavijo se lahko pri več kot 1 od 10 oseb
If you stop using Lyxumia, your blood sugar levels can increase. 
Če prenehate uporabljati zdravilo Lyxumia, se vam lahko koncentracija krvnega sladkorja zviša.
Following administration of a single dose of paracetamol 1,000 mg, paracetamol AUC and t1/2 were unchanged whatever the timing of its administration (before or after the lixisenatide injection). 
Po uporabi enega samega odmerka 1000 mg paracetamola se AUC in t1/2 paracetamola nista spremenila, ne glede na čas uporabe (pred injiciranjem liksisenatida ali po njem).
Lixisenatide provided significant improvements in HbA1c (-0.64% change compared to placebo; 95% CI: -0.810% to -0.464%; p<0.0001), from a mean baseline HbA1c of 8.0%. 
Liksisenatid je v primerjavi s placebom značilno izboljšal HbA1c (-0,64 % v primerjavi s placebom, 95 % IZ: -0,810 % do -0,464 %, p < 0,0001) s povprečnega izhodiščnega HbA1c 8,0 %.
Irrespective of the dose and whether lixisenatide was administered as single or multiple doses, the median tmax is 1 to 3.5 hours in patients with type 2 diabetes. 
Ne glede na odmerek in ne glede na to, ali je bil liksisenatid uporabljen v enkratnem odmerku ali v večkratnih odmerkih, je bil mediani tmax pri sladkornih bolnikih tipa 2 od 1 do 3,5 ure.
How much to inject 
Koliko zdravila injicirati
Efficacy of Lyxumia was also assessed in two randomised, open-label, active-controlled study (versus exenatide or versus insulin glulisine) and in a meal time study (in total 1,067 patients randomised to lixisenatide). 
Učinkovitost zdravila Lyxumia so ocenili tudi v dveh randomiziranih, odprtih, z zdravilno učinkovino kontroliranih študijah (v primerjavi z eksenatidom ali v primerjavi z insulinom glulisinom) in v študiji ob obroku (skupno 1.067 bolnikov randomiziranih na liksisenatid).
Do not stop using Lyxumia without talking with your doctor. 
Če ste prenehali uporabljati zdravilo Lyxumia Ne prenehajte uporabljati zdravila Lyxumia, ne da bi se posvetovali s svojim zdravnikom.
• Cold (upper respiratory tract infection) 
• prehlad (okužba zgornjih dihal)
People aged ≥70 years The efficacy and safety of lixisenatide in people aged ≥70 years with type 2 diabetes was evaluated in a double-blind, placebo-controlled study of 24 weeks duration. 
Učinkovitost in varnost liksisenatida pri osebah, starih ≥ 70 let in s sladkorno boleznijo tipa 2, so ocenili v dvojno slepi, s placebom kontrolirani 24-tedenski študiji.
Pull the needle out of your skin. 
Potegnite iglo iz kože.
If you miss a dose of Lyxumia, you can inject it in the hour before your next meal. 
Če ste izpustili odmerek zdravila Lyxumia, si ga lahko injicirate v uri pred naslednjim obrokom.
• Cardiovascular evaluation 
• Kardiovaskularni parametri
Median treatment duration was 22.4 months in the lixisenatide group and 23.3 months in the placebo group, and the median duration of study follow-up was 25.8 and 25.7 months, respectively. 
Mediano trajanje zdravljenja je bilo 22,4 meseca v skupini z liksisenatidom in 23,3 meseca v skupini s placebom, mediano trajanje spremljanja pa je bilo v prvi 25,8 meseca in v drugi 25,7 meseca.
Overall, 6068 patients were randomized 1:1 to either placebo or lixisenatide 20 mcg (following a starting dose of 10 mcg during the first 2 weeks). 
V celoti so 6068 bolnikov v razmerju 1:1 randomizirali ali na placebo ali na 20 mikrogramov liksisenatida (po začetnem odmerku 10 mikrogramov v prvih 2 tednih).